Gina Mazzariello Sells 9,536 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 9,536 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the sale, the insider directly owned 190,838 shares of the company’s stock, valued at approximately $6,194,601.48. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gina Mazzariello also recently made the following trade(s):

• On Thursday, July 9th, Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00.

Amylyx Pharmaceuticals Trading Up 6.4%

AMLX stock traded up $2.02 during trading on Monday, reaching $33.64. The stock had a trading volume of 1,816,910 shares, compared to its average volume of 1,682,389. The firm has a fifty day moving average price of $25.69 and a 200 day moving average price of $18.87. The company has a market capitalization of $3.75 billion, a P/E ratio of -23.52 and a beta of -0.13. Amylyx Pharmaceuticals, Inc. has a 1-year low of $10.83 and a 1-year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AMLX. KBC Group NV acquired a new position in Amylyx Pharmaceuticals in the first quarter worth $26,000. State of Wyoming acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth $40,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Amylyx Pharmaceuticals by 954.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth about $157,000. Finally, ACT Capital Management LLC bought a new position in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $109,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Citigroup lifted their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Robert W. Baird upped their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Finally, Mizuho increased their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $36.50.

Amylyx Pharmaceuticals Company Profile